Evaluation of galectin-3 levels in acute coronary syndrome

İpek, Esra Gücük; Suljevic, Senay Akin; Kafes, Habibe; Başyiğit, Funda; Karalok, Neslihan; Güray, Yeşım; Asarcıklı, Lale Dinç; Acar, Berrin; Demirel, Haydar A.

doi:10.1016/j.ancard.2015.09.046

Cited by 23 publications

(15 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The comparative study between the two groups shows a significant difference (P = 0.001). These results were in agreement with the results reported by E. Gucuk Ipeka et al, study [14].…”

Section: Discussionsupporting

confidence: 94%

“…The association between Gensini scores and galectin-3 suggests that galectin-3 may predict the severity of the coronary artery disease in clinical practice, and may become an additional tool in identifying high-risk patients. These results were in agreement with the results reported by E. Gucuk Ipek a et al, [14].…”

Section: Discussionsupporting

confidence: 94%

“…We observed that galectin 3 in acute coronary syndrome has high sensitivity compared to E. Gucuk Ipek a et al [14] and this result may refer to a large number of patients compared to that study which has nineteen patients with acute coronary syndrome and seventeen age matched controls while we have seventy two patients with acute coronary syndrome and twenty age matched control. Also previous studies also reported similar findings as Falcone C. et al [15] and also Menini S. et al [16].…”

Section: Discussionsupporting

confidence: 38%

See 2 more Smart Citations

Galectin 3 Level in Patients with Acute Coronary Syndrome and its Relation to Severity of Coronary Artery Disease

Soltan¹,

Samy²,

Mashal³

2020

WJCD

View full text Add to dashboard Cite

“…The comparative study between the two groups shows a significant difference (P = 0.001). These results were in agreement with the results reported by E. Gucuk Ipeka et al, study [14].…”

Section: Discussionsupporting

confidence: 94%

Section: Discussionsupporting

confidence: 94%

Section: Discussionsupporting

confidence: 38%

See 1 more Smart Citation

Galectin 3 Level in Patients with Acute Coronary Syndrome and its Relation to Severity of Coronary Artery Disease

Soltan¹,

Samy²,

Mashal³

2020

WJCD

View full text Add to dashboard Cite

“…In patients with coronary artery disease, serum galectin-3 levels exhibited a significantly positive association with coronary artery disease severity, as determined by the Gensini score and number of diseased vessels ( 65 ), and increased serum levels of galectin-3 reflected the increased degree of myocardial fibrosis ( 66 ). Contrastingly, in patients with acute coronary syndrome, serum galectin-3 levels demonstrated a significantly positive association with the Gensini score; however, not with the number of diseased vessels ( 67 ). In addition, acute coronary syndrome patients with higher galectin-3 expression levels exhibited a decreased LVEF and eGFR ( 68 ).…”

Section: Galectin-3 and Cardiovascular Diseasementioning

confidence: 73%

Galectin-3 as a novel biomarker for disease diagnosis and a target for therapy (Review)

et al. 2017

View full text Add to dashboard Cite

Galectin-3 is a member of the galectin family, which are β-galactoside-binding lectins with ≥1 evolutionary conserved carbohydrate-recognition domain. It binds proteins in a carbohydrate-dependent and -independent manner. Galectin-3 is predominantly located in the cytoplasm; however, it shuttles into the nucleus and is secreted onto the cell surface and into biological fluids including serum and urine. It serves important functions in numerous biological activities including cell growth, apoptosis, pre-mRNA splicing, differentiation, transformation, angiogenesis, inflammation, fibrosis and host defense. Numerous previous studies have indicated that galectin-3 may be used as a diagnostic or prognostic biomarker for certain types of heart disease, kidney disease and cancer. With emerging evidence to support the function and application of galectin-3, the current review aims to summarize the latest literature regarding the biomarker characteristics and potential therapeutic application of galectin-3 in associated diseases.

show abstract

“…We measured galectin-3 on the third day after admission when it was decreasing, while TnI was in the “wash-out phase” after PCI and possibly had a secondary peak [19]. Patients with higher galectin-3 levels had ticagrelor more often than clopidogrel in therapy, which could be explained by the larger atherosclerotic burden in those patients, observed in earlier studies [20]. The average levels of galectin-3 in our patients were lower than those reported in younger healthy individuals [21].…”

Section: Discussionmentioning

confidence: 94%

Galectin-3 in Acute Myocardial Infarction Patients with Atrial Fibrillation

et al. 2019

View full text Add to dashboard Cite

Objective: Atrial fibrillation (AF) is common in acute myocardial infarction (AMI), and galectin-3 is possibly involved in its occurrence. Galectin-3 has been shown to play a central role in fibrosis and tissue remodeling and has a role in inflammatory and proliferative responses. The aim of our study was to measure galectin-3 levels in patients with myocardial infarction and to compare its levels in patients with or without AF, in order to investigate the potential predictive role of galectin-3 in this setting. Subjects and Methods: The study included 51 consecutive AMI patients with AF; 27 AMI patients (52.9%) had permanent/persistent AF, and 24 patients (47.1%) had paroxysmal AF. Thirty-eight consecutive AMI patients without AF were used as a control group. Blood samples were obtained from venous blood on the third day after reperfusion. Results: Patients with AF had higher levels of C-reactive protein (p < 0.01) and galectin-3 (p < 0.05) than those without AF. Patients with high galectin-3 had 4.4 times greater odds of having AF. Galectin-3 levels were lower in patients without AF (p < 0.01) than in those with permanent/persistent AF. Conclusion: AMI patients with AF had higher levels of galectin-3 than those without this arrhythmia. This biomarker of inflammation and fibrosis could be a potential target for treating AMI patients at high risk.

show abstract

Evaluation of galectin-3 levels in acute coronary syndrome

Cited by 23 publications

References 29 publications

Galectin 3 Level in Patients with Acute Coronary Syndrome and its Relation to Severity of Coronary Artery Disease

Galectin 3 Level in Patients with Acute Coronary Syndrome and its Relation to Severity of Coronary Artery Disease

Galectin-3 as a novel biomarker for disease diagnosis and a target for therapy (Review)

Galectin-3 in Acute Myocardial Infarction Patients with Atrial Fibrillation

Contact Info

Product

Resources

About